DOCSLIB.ORG

Recent Advances in Doping Analysis (28)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent Advances in Doping Analysis (28) M. THEVIS H. GEYER U. MARECK (EDITORS) RECENT ADVANCES IN DOPING ANALYSIS (28) Proceedings of the Manfred Donike Workshop 38th Cologne Workshop on Dope Analysis 9th to 14th February 2020 SPORTVERLAG Strauß - Hellenthal 2020 1 Bibliografische Information Der Deutschen Nationalbibliothek Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über <http://dnb.d-nb.de> abrufbar. Thevis, Mario; Geyer, Hans; Mareck, Ute (Eds.) Recent Advances in Doping Analysis (28). Proceedings of the Manfred Donike Workshop, 38th Cologne Workshop on Dope Analysis, 9th to 14nd February 2020 / [MDI e.V.] – 2020 Sportverlag Strauß. ISBN 978-3-86884-046-9 ©SPORTVERLAG Strauß Neuhaus 12 – 53940 Hellenthal Tel. +49 (0)2448/2470040 – Fax +49 (0)2448/9195610 E-mail: [email protected] www.sportverlag-strauss.de Satz: Autorensatz 2 MANFRED DONIKE WORKSHOP 2020 TABLE OF CONTENTS PAGE LECTURES Marchand A, Ericsson M, Audran M, Fenaille F, Capdeville P, Martin L: EPO Biosimilars with unusual profiles: characterization and detection .................................... 13-22 Heiland CE, Masquelier M: Sepharose gel beads: an effective technique for recombinant erythropoietin immuno- purification from blood ................................................................................................................ 23-27 POSTER PRESENTATIONS Sigmund G, Geyer H, Goergens C, Thevis M: Prevalence of the imidazole derivatives naphazoline, oxymetazoline and xylometa- zoline in doping control samples ................................................................................................. 28-31 Wicka M, Kaliszewski P, Grucza K, Stanczyk D, Drapala A, Konarski P, Zalewska Z, Siek P, Michalak D, Kwiatkowska D: Elimination profile of triamcinolone acetonide and its metabolite in human urine after multiple transdermal administrationed stimulants .................................................................... 32-36 Barbán Duarte L, Martínez Brito D, Correa Vidal T, Montes de Oca Porto R: Trend analysis and decision making in the Havana Anti-Doping Laboratory ............................. 37-40 Rodriguez Fernandez A, Laffita D, López Castillo D, Terrero O, Montes de Oca R: Increase in the incidence of THC in urine samples of athletes in 2019 ....................................... 41-45 Biasini GM, Donati F, Rutigliano L, de La Torre X, Botrè F: Proteomic analysis of biomarkers of red blood cells storage: towards the development of direct detection of autologous blood transfusion ................................................................... 46-51 Donati F, Botrè F, de La Torre X, Sian V, Biasini GM, Concetti L, Rutigliano L: Evaluation of the impact of genetic polymorphisms on basal values of human serum and urinary biomarkers: implications for anti-doping analyses ................................................. 52-58 3 PAGE Momobayashi A, Kageyama S, Okano M: Detection of homologous blood transfused erythrocytes by means of a two color fluorescence flow cytometric analysis ......................................................................................... 59-62 Zhou X, He S, Zhang L, Shen L, He C: Administration Study of rEPOs circulated in China ................................................................................... 63-67 He S, Zhou X, Zhang L, Shen L, He C: Troubleshooting for doping analysis of EPO ................................................................................ 68-70 Somay Selbes Y, Onol S, Kacar T, Demirel AH, Aytekin S: Effects of protease inhibitors on stability of urine hCG and LH in doping analyses ................... 71-73 Iannone M, Botrè F, de La Torre X: Direct and indirect detection of pseudo-endogenous steroids in plasma .................................. 74-79 Son J, Park JW, Lee SH: Multiple Biomarkers of Anabolic Agent Administration in Urine as Candidates for Doping Diagnosis ........................................................................................................................... 80-84 Danila G, Pop A, Toboc A, Stan C: 7-Keto-DHEA – a case study .......................................................................................................... 85-89 Geyer H, Fusshöller G, Haenelt N, Mareck U, Blatt C, Gougoulidis V, Hülsemann F, Piper T, Thevis M: The ratio 5aAdiol/E as indicator for the detection of testosterone doping in athletes with naturally low T/E – a case study ........................................................................................... 90-93 Wen C, Liu X, Tianshuo Z, Jingzhu W: Isolation of boldenone and its metabolite in urine sample and further determination of the C/ C ratios by gas chromatographycombustion-isotope ratio mass spectrometry ............. 94-97 Mabusa I, Du Preez H, van der Merwe T: Proposed suppression of phentermine derivatization by concomitant medication: A GC-MS case study and suggested solution ............................................................................. 98-102 Kaewklum M, Kaewklum S, Dithayam S, Wilairat P, Kongpatanakul S: Separation and identification of regioisomers of fluoroamphetamine and fluorometh- amphetamine in doping control by gas chromatography-mass spectrometry ...................... 103-107 Stacchini C, Dima AP, de La Torre X, Mazzarino M, Botrè F: In vitro studies of the metabolic profile of different classes of SARMs using liquid chromatographic-mass spectrometric techniques .................................................................. 108-112 Songsaeng R, Saardpun N, Kusamran T, Kongpatanakul S: Method Development for Identification of Growth Hormone Releasing Peptides (GHRPs) in Doping Control by UFLC/MS-IT-TOF ....................................................................... 113-117 4 PAGE Ahi S, Dubey S, Bhardwaj A, Sahu PL: Fast and sensitive detection of small peptides in human urine using liquid chroma- tography tandem mass spectrometry .............................................................................................. 118-123 Berghes B, Radu M, Cristea CD, Toboc A, Stan C: Validation of HIF activating agents confirmation methods ......................................................... 124-128 Grucza K, Wicka M, Drapala A, Konarski P, Stanczyk D, Michalak D, Kaliszewski P, Kwiatkowska D: Impact of various purity grades of acetonitrile and different mass spectrometry ionization methods on limits of detection of dopingsubstances by means of the “Dilute- and-Shoot” approach .......................................................................................................................... 129-133 Alechaga E, Terrero A, Monfort N, Ventura R: UHPLC-HRMS multi-screening method for doping control analyses in urine samples ........... 134-138 de la Cal A, Espinosa P, Blázquez I, Fernández B, García L, de Pedraza L, Carreras D, Muñoz G: Solving problems with HILIC columns: Compounds with difficult chromatographic behavior................................................................................................................................................. 139-143 Fernández-Álvarez M, Cuervo D, Baltazar-Martins JG, Plata MDM, Muñoz-Guerra JA, Lara B, Del Coso J, Muñoz G, Carreras D: Determination of tramadol and its metabolites in plasma by using liquid chroma- tography quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS) ................................. 144-148 Cuervo D, Fernández-Álvarez M, Baltazar-Martins JG, Plata MDM, Muñoz-Guerra JA, Lara B, Del Coso J, Muñoz G, Carreras D: Determination of tramadol and its metabolites in urine via accuratemass quadrupole time-of-flight (Q-TOF) LC/MS ............................................................................................................ 149-152 PRESENTATIONS ABSTRACTS - LECTURES Gotzmann A: "Operation Aderlass”: Legislation as a cornerstone of anti-doping .............................................. 153 Rossi F, Saugy M: Dried Blood Spots: Alternative matrix to deter and detect Tramadol abuse in road cycling competitions ........................................................................................................................ 154 Knoop A, Planitz P, Wuest B, Thevis M: Evaluation of cobalt in doping control samples: Discrimination of different cobalt sources .............................................................................................................................................. 155 Paßreiter A, Thomas A, Walpurgis K, Thevis M: First steps towards uncovering gene doping with CRISPR/Cas9 .................................................... 156 5 PAGE Coll S, Monfort N, Alechaga &, Matabosch X, Pérez-Mañà C, Ventura R: Evaluation of the reporting level to detect betamethasone misuse in sports: additional studies after intranasal and intramuscular administrations .......................................................... 157 Walpurgis K, Rubio A, Wagener F, Krug O, Knoop A, Görgens C, Guddat S, Thevis M: Elimination profiles of microdosed ostarine mimicking contaminated products ingestion .................................................................................................................................................... 158-159 Garzinsky A, Thomas A, Krug O, Thevis M: Exhaled breath in doping controls: characterization of SensAbues® sampling devices using an aerosol test generator ....................................................................................................... 160 Mongongu C, Ericsson M, Madi Moussa E, Audran
Load more

Recommended publications
  • Relation Between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping
    biology Review Relation between Exercise Performance and Blood Storage Condition and Storage Time in Autologous Blood Doping Benedikt Seeger and Marijke Grau * Molecular and Cellular Sports Medicine, German Sport University Cologne, 50677 Cologne, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-221-4982-6116 Simple Summary: Autologous blood doping (ABD) refers to sampling, storage, and re-infusion of one’s own blood to improve circulating red blood cell (RBC) mass and thus the oxygen transport and finally the performance capacity. This illegal technique employed by some athletes is still difficult to detect. Hence knowledge of the main effects of ABD is needed to develop valid detection methods. Performance enhancement related to ABD seems to be well documented in the literature, but applied study designs might affect the outcome that was analyzed herein. The majority of recent studies investigated the effect of cold blood storage at 4 ◦C, and only few studies focused on cryopreservation, although it might be suspected that cryopreservation is above all applied in sport. The storage duration—the time between blood sampling and re-infusion—varied in the reported literature. In most studies, storage duration might be too short to fully restore the RBC mass. It is thus concluded that most reported studies did not display common practice and that the reported performance outcome might be affected by these two variables. Thus, knowledge of the real effects of ABD, as applied in sport, on performance and associated parameters are needed to develop reliable detection techniques. Abstract: Professional athletes are expected to continuously improve their performance, and some might also use illegal methods—e.g., autologous blood doping (ABD)—to achieve improvements.
    [Show full text]
  • Deporte Y COVID-19
    Sociología del Deporte Número 1. Junio 2020. ISSN: 2660-8456 Número Especial Deporte y COVID-19 Presentación de la revista Sociología del Deporte (SD) surge con el propósito de crear un espacio de re- flexión y debate en torno al fenómeno deportivo desde la perspectiva de las ciencias sociales. Pretende conectar desde el rigor científico las principales teorías y corrien- tes de la sociología —pero también las propias de disciplinas afines (antropología, historia, psicología social, ciencias del deporte y filosofía política y moral)— con el debate intelectual de nuestro tiempo en torno al fenómeno deportivo. Promueve el estudio del fenómeno deportivo como expresión de la realidad social y anima a ana- lizar los hechos y cambios sociales a través del deporte. Por lo tanto, la revista está abierta al conjunto de investigadores e investigadoras de las ciencias sociales, con independencia de su grado de especialización. Sociología del Deporte (SD) inicia su publicación en 2020 con periodicidad se- mestral, en formado a papel y electrónico. Comparte los principios éticos de otras publicaciones que emplean el sistema Acceso Abierto (Open Access). Publicará tra- bajos científicos originales e inéditos de carácter empírico o teórico y notas sobre investigaciones sociológicas o áreas afines. También publicará secciones de deba- tes, estados de la cuestión, secciones monográficas y contenidos de especial interés para la comunidad sociológica. Sociología del Deporte aspira a alcanzar la mayor ca- lidad posible en los trabajos que publique, por lo que utiliza un sistema arbitrado de revisión externa por expertos (Peer Review). Desea convertirse en una publicación de referencia internacional, con vocación de integrar los debates existentes en torno al fenómeno deportivo en España, Europa, Latinoamérica, y el resto del mundo.
    [Show full text]
  • Sim Nowell Paolo Q. Sim 3LM2 Trivia About Spain
    Sim Nowell Paolo Q. Sim 3LM2 Trivia about Spain: 1. Spain is the third most visited country in the world according to the World Tourism rankings (2013) that are compiled by the United Nations World Tourism Organization. Spain claims this place with a whopping 60.7 million international tourists and are only surpassed by USA and France. 2. There is a pretty controversial law that shop signs in Catalonia must be written in both Catalan and in Spanish. The law also requires radio and television stations to broadcast a minimum quota of their shows in Catalan. 3. The King of Spain nominates a candidate for presidency. 4. Bull fighting is a traditional event in Spain and are in Spanish called called "a corrida de toros" which literally means "running of bulls". The Bullfighting season starts in March and continues through the end of October and the minimum weight of a bullfighting bull is 460 kg (1010 lbs). 5. Spain includes a number of islands including Mallorca, Tenerife, Ibiza and Gran Canaria. Many can be found in the Canary Islands, an archipelago off the northwest coast of Africa. 6. The Spanish tourism industry is one of the largest in the world, bringing in billions of Euros into the Spanish economy. 7. Spain produces a large amount of renewable energy, including wind power and solar power. 8. Spain has a variety of foods and unique dishes such as paella (a type of rice dish) and tapas (a range of small snacks or appetizers). 9. Football (soccer) is the most popular sport in Spain.
    [Show full text]
  • ESSA-Sport National Report - Spain 1
    ESSA-Sport National Report - Spain 1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................ 2 1. THE ESSA-SPORT PROJECT AND BACKGROUND TO THE NATIONAL REPORT ........................................ 4 2. NATIONAL KEY FACTS AND OVERALL DATA ON THE LABOUR MARKET ............................................... 8 3. THE NATIONAL SPORT AND PHYSICAL ACTIVITY SECTOR .................................................................. 16 4. SPORT LABOUR MARKET STATISTICS ............................................................................................... 48 5. NATIONAL EDUCATION AND TRAINING SYSTEM .............................................................................. 67 6. NATIONAL SPORT EDUCATION AND TRAINING SYSTEM ................................................................... 83 7. FINDINGS FROM THE EMPLOYER SURVEY ........................................................................................ 93 8. REPORT ON NATIONAL CONSULTATIONS ...................................................................................... 106 9. NATIONAL CONCLUSIONS ............................................................................................................. 108 10. NATIONAL ACTION PLAN AND RECOMMENDATIONS ................................................................... 113 BIBLIOGRAPHY AND SOURCES .......................................................................................................... 116
    [Show full text]
  • The 2006 Prohibited List International Standard
    The World Anti-Doping Code THE 2006 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2006. THE 2006 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2006 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone
    [Show full text]
  • Roxadustat for the Treatment of Anemia Due to Chronic Kidney
    Roxadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients not on Dialysis and on Dialysis FDA Presentation Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021 Clinical: Saleh Ayache, MD Division of Non-Malignant Hematology Office of Cardiology, Hematology, Endocrinology, and Nephrology Statistics: Jae Joon Song, PhD Division of Biometrics VII/Office of Biostatistics www.fda.gov Roxadustat Review Team • Clinical • Quality Assessment • Biopharmaceutics Saleh Ayache Ben Zhang Joan Zhao Ann T. Farrell Dan Berger • Labeling Nancy Waites Ellis Unger Virginia Kwitkowski • Clinical Pharmacology • Project Management • Clinical Outcome Assessment Snehal Samant Alexis Childers Naomi Knoble Jihye Ahn Courtney Hamilton • Division of Hepatology and Nutrition Sudharshan Hariharan Paul H. Hayashi • Pharmacology Toxicology Doanh Tran Mark Avigan Geeta Negi • Statistics • Office of Scientific Investigations Todd Bourcier Lola Luo Anthony Orencia Jae Joon Song Clara Kim Yeh-Fong Chen Thomas Gwise Mat Soukup www.fda.gov 2 Outline of Presentation • Product and proposed indication • Regulatory history and background • Roxadustat development program • Efficacy Safety • Adverse events • Major adverse cardiovascular events • All-cause mortality • Exploratory analyses of the relationships between thromboembolic events, drug dose, hemoglobin, and rate of change of hemoglobin www.fda.gov 3 Product and Proposed Indication • Roxadustat: small-molecule, oral, hypoxia inducible- factor prolyl-hydroxylase inhibitor (HIF-PHI),
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • The Influence of Inflammation on Anemia in CKD Patients
    International Journal of Molecular Sciences Review The Influence of Inflammation on Anemia in CKD Patients Anna Gluba-Brzózka 1,* , Beata Franczyk 1, Robert Olszewski 2 and Jacek Rysz 1 1 Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland; [email protected] (B.F.); [email protected] (J.R.) 2 Department of Geriatrics, National Institute of Geriatrics Rheumatology and Rehabilitation and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (IPPT PAN), 02-106 Warsaw, Poland; [email protected] * Correspondence: [email protected] Received: 18 November 2019; Accepted: 19 January 2020; Published: 22 January 2020 Abstract: Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient’s life. It also enhances morbidity and mortality and hastens the CKD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Final Evidence Report
    Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value Final Evidence Report March 5, 2021 Prepared for ©Institute for Clinical and Economic Review, 2021 ICER Staff and Consultants University of Washington Modeling Group Reem A. Mustafa, MD, MPH, PhD Lisa Bloudek, PharmD, MS Associate Professor of Medicine Senior Research Scientist Director, Outcomes and Implementation Research University of Washington University of Kansas Medical Center Josh J. Carlson, PhD, MPH Grace Fox, PhD Associate Professor, Department of Pharmacy Research Lead University of Washington Institute for Clinical and Economic Review The role of the University of Washington is limited to Jonathan D. Campbell, PhD, MS the development of the cost-effectiveness model, and Senior Vice President for Health Economics the resulting ICER report does not necessarily Institute for Clinical and Economic Review represent the views of the University of Washington. Foluso Agboola, MBBS, MPH Vice President of Research Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review David M. Rind, MD, MSc Chief Medical Officer Institute for Clinical and Economic Review None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: March 5, 2021 How to cite this document: Mustafa RA, Bloudek L, Fox G, Carlson JJ, Campbell JD, Agboola F, Pearson SD, Rind DM. Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value; Final Evidence Report. Institute for Clinical and Economic Review, March 5, 2021. https://icer.org/assessment/anemia-in-chronic-kidney-disease-2021/#timeline. Reem Mustafa served as the lead author for the report. Grace Fox led the systematic review and authorship of the comparative clinical effectiveness section in collaboration with Foluso Agboola and Noemi Fluetsch.
    [Show full text]